Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRAD P GLICK

Allopathic & Osteopathic Physicians Dermatology

NPI
1235134818
CMS profile
55271
Location
MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$405,391.50

419 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRAD P GLICK

NPI 1235134818 · CMS profile ID 55271

Allopathic & Osteopathic Physicians / Dermatology

MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235134818?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRAD P GLICK, NPI 1235134818, CMS profile ID 55271. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235134818?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BRAD P GLICK, NPI 1235134818, CMS profile ID 55271. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235134818?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BRAD P GLICK, NPI 1235134818, CMS profile ID 55271, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 419 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1235134818?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

419 matching records · $405,391.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 419 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 419.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Galderma Laboratories, L.P. $9.7211/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234645465 CMS
ABBVIE INC. $2,550.0011/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201931169 CMS
Lilly USA, LLC $1,600.0011/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186527571 CMS
LNHC, Inc $2,625.0011/06/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1242602448 CMS
Organon LLC $7.2711/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237676036 CMS
UCB, Inc. $139.7011/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405999 CMS
Incyte Corporation $3,000.0011/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226024594 CMS
ABBVIE INC. $10.8511/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201931167 CMS
Regeneron Healthcare Solutions, Inc. $3.0511/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212928745 CMS
Regeneron Healthcare Solutions, Inc. $28.7611/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212928743 CMS
Eli Lilly and Company $1,600.0010/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186527573 CMS
ABBVIE INC. $2.5410/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201931165 CMS
Galderma Laboratories, L.P. $4.8610/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234645461 CMS
Incyte Corporation $124.9910/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226024610 CMS
MAYNE PHARMA COMMERCIAL LLC $5.3410/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254348616 CMS
STRATA Skin Sciences, Inc. $11.4710/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253014456 CMS
GENZYME CORPORATION $32.2810/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233282591 CMS
Amgen Inc. $126.6610/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228388657 CMS
ABBVIE INC. $54.6210/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201931163 CMS
LNHC, Inc $188.5510/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242602446 CMS
UCB, Inc. $45.4610/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405997 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $88.8410/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250975096 CMS
E.R. Squibb & Sons, L.L.C. $20.0010/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184843565 CMS
E.R. Squibb & Sons, L.L.C. $20.0010/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184843567 CMS
Regeneron Healthcare Solutions, Inc. $33.6410/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212928741 CMS
ABBVIE INC. $8.5310/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201931159 CMS
ABBVIE INC. $5,950.0010/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201931161 CMS
Novartis Pharmaceuticals Corporation $22.0010/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200294747 CMS
Organon LLC $9.7010/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237676038 CMS
Regeneron Healthcare Solutions, Inc. $5,551.0010/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212928739 CMS
Novartis Pharmaceuticals Corporation $22.6810/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200294743 CMS
Novartis Pharmaceuticals Corporation $0.9710/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200294745 CMS
GENZYME CORPORATION $11,284.0010/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233282635 CMS
Janssen Biotech, Inc. $4,050.0010/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175132500 CMS
ABBVIE INC. $7.2010/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201931157 CMS
Galderma Laboratories, L.P. $5.0010/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234645459 CMS
Regeneron Healthcare Solutions, Inc. $767.6110/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212928737 CMS
Incyte Corporation $750.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226027851 CMS
Janssen Biotech, Inc. $149.9910/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175132432 CMS
Kowa Pharmaceuticals America, Inc. $750.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1243089436 CMS
ABBVIE INC. $5,950.0010/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201931155 CMS
Lilly USA, LLC $1,600.0010/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186534701 CMS
Galderma Laboratories, L.P. $6.4110/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234645457 CMS
Regeneron Healthcare Solutions, Inc. $1.3410/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212928733 CMS
Regeneron Healthcare Solutions, Inc. $24.8410/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212928735 CMS
LEO Pharma Inc. $9.5010/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252007164 CMS
LEO Pharma Inc. $10.9210/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252007166 CMS
Lilly USA, LLC $2,400.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186534703 CMS
Novartis Pharmaceuticals Corporation $27.9410/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200294741 CMS
GENZYME CORPORATION $29.0510/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233282583 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $213,551.04 331
PY2020 $155,308.64 195
PY2021 $197,871.42 217
PY2022 $321,954.67 333
PY2023 $367,021.69 349
PY2024 $380,351.23 426
PY2025 $405,391.50 419

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $344,231.01 142
PY2024 Principal investigator $874,375.49 397
PY2023 Principal investigator $152,321.61 58
PY2022 Principal investigator $96,349.78 31
PY2021 Principal investigator $208,888.57 30
PY2020 Recipient $324.60 1
PY2020 Principal investigator $225,111.96 38
PY2019 Principal investigator $119,709.96 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533001
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533003
Principal investigator 1 Amgen Inc. $3,600.00 12/24/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246641996
Principal investigator 1 Amgen Inc. $7,100.00 12/24/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246642000
Principal investigator 1 ABBVIE INC. $1,892.10 12/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527062
Principal investigator 1 ABBVIE INC. $3,104.13 12/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202527064
Principal investigator 1 ABBVIE INC. $21,865.65 12/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527066
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537415
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537420
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537424
Principal investigator 1 Incyte Corporation $1,800.00 11/12/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537441
Principal investigator 1 Incyte Corporation $1,500.00 11/12/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537444
Principal investigator 1 ABBVIE INC. $35,066.25 11/05/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522849
Principal investigator 1 ABBVIE INC. $2,167.50 11/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521065
Principal investigator 1 ABBVIE INC. $7,001.64 11/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202521067
Principal investigator 1 ABBVIE INC. $2,002.00 11/04/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521069
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 10/29/2025 Non-covered Recipient Entity
Gsi Clinical Research
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226083305
Principal investigator 1 Incyte Corporation $2,500.00 10/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537402
Principal investigator 1 Incyte Corporation $10,000.00 10/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537428
Principal investigator 1 Incyte Corporation $1,200.00 10/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537432
Principal investigator 1 Incyte Corporation $1,800.00 10/13/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537406
Principal investigator 1 Incyte Corporation $500.00 10/13/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537437
Principal investigator 1 Incyte Corporation $1,500.00 10/13/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537449
Principal investigator 1 ABBVIE INC. $34,800.30 10/09/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514205
Principal investigator 1 Incyte Corporation $1,413.00 09/10/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537393
Principal investigator 1 ABBVIE INC. $2,502.50 09/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507779
Principal investigator 1 ABBVIE INC. $3,004.68 09/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507781
Principal investigator 1 ABBVIE INC. $500.50 08/06/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503089
Principal investigator 1 ABBVIE INC. $3,000.00 08/05/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202501772
Principal investigator 1 Incyte Corporation $1,984.50 07/09/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537397
Principal investigator 1 ABBVIE INC. $2,380.00 07/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495491
Principal investigator 1 ABBVIE INC. $1,695.00 07/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495493
Principal investigator 1 ABBVIE INC. $1,636.20 07/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495495
Principal investigator 1 ABBVIE INC. $500.50 07/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495497
Principal investigator 1 ABBVIE INC. $3,854.22 07/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202495613
Principal investigator 1 ABBVIE INC. $6,858.90 06/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202488757
Principal investigator 1 ABBVIE INC. $3,681.45 06/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202488759
Principal investigator 1 ABBVIE INC. $2,054.00 06/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489477
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 05/28/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193776
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 05/28/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 05/21/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184197479
Principal investigator 1 ABBVIE INC. $4,483.69 05/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482815
Principal investigator 1 ABBVIE INC. $2,054.00 05/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482885
Principal investigator 1 ABBVIE INC. $3,388.50 05/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482887
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193800
Principal investigator 1 Janssen Research & Development, LLC $454.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193809
Principal investigator 1 Janssen Research & Development, LLC $508.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193816
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193832
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193843
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193850
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193866
Principal investigator 1 Janssen Research & Development, LLC $2,526.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193874
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193884
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193909
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193919
Principal investigator 1 Janssen Research & Development, LLC $250.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193927
Principal investigator 1 Janssen Research & Development, LLC $704.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193958
Principal investigator 1 Janssen Research & Development, LLC $254.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193964
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193991
Principal investigator 1 Janssen Research & Development, LLC $2,526.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194010
Principal investigator 1 Janssen Research & Development, LLC $2,526.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194027
Principal investigator 1 Janssen Research & Development, LLC $254.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194044
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194051
Principal investigator 1 Janssen Research & Development, LLC $2,526.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194057
Principal investigator 1 Janssen Research & Development, LLC $1,895.00 05/07/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194065
Principal investigator 1 ABBVIE INC. $5,500.00 05/06/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202481533
Principal investigator 1 Incyte Corporation $1,172.70 05/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537316
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 04/28/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193900
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 04/28/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194016
Principal investigator 1 Incyte Corporation $2,205.00 04/09/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537325
Principal investigator 1 ABBVIE INC. $2,054.00 04/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202469233
Principal investigator 1 ABBVIE INC. $1,338.60 04/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202471574
Principal investigator 1 ABBVIE INC. $2,291.10 04/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202471577
Principal investigator 1 Incyte Corporation $54.76 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537312
Principal investigator 1 Incyte Corporation $64.72 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537321
Principal investigator 1 Incyte Corporation $14.84 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537329
Principal investigator 1 Incyte Corporation $59.13 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537333
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537337
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537342
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537346
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537349
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537353
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537358
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537362
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537366
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537370
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537373
Principal investigator 1 Incyte Corporation $62.27 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537377
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537381
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537385
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537390
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 03/24/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193785
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 03/24/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193935
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 03/24/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193983
Principal investigator 1 Incyte Corporation $1,393.20 03/12/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537182
Principal investigator 1 ABBVIE INC. $6,345.00 03/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202460467
Principal investigator 1 ABBVIE INC. $6,587.46 03/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202460471
Principal investigator 1 ABBVIE INC. $1,001.00 03/07/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460637
Principal investigator 1 Incyte Corporation $125.95 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537228
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537232
Principal investigator 1 Incyte Corporation $236.52 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537245
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537250
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537255
Principal investigator 1 Incyte Corporation $406.20 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537259
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537271
Principal investigator 1 Incyte Corporation $0.93 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537275
Principal investigator 1 Incyte Corporation $19.44 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537281
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537297
Principal investigator 1 Incyte Corporation $24.66 03/03/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537301
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193794
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193824
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193892
Principal investigator 1 Janssen Research & Development, LLC $2,916.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193942
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193950
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193973
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 02/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175194000
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,425.00 02/21/2025 Non-covered Recipient Entity
Glick Skin Institute
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis No dispute reported 06/30/2026 1235997087
Principal investigator 1 Incyte Corporation $1,645.00 02/10/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537236
Principal investigator 1 Incyte Corporation $1,548.00 02/10/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537263
Principal investigator 1 Incyte Corporation $1,548.00 02/10/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537267
Principal investigator 1 ABBVIE INC. $4,320.00 02/06/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202447309
Principal investigator 1 ABBVIE INC. $11,635.09 02/06/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202448295
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 01/27/2025 Non-covered Recipient Entity
Gsi Clinic Rsrch
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175193860
Principal investigator 1 Incyte Corporation $1,710.00 01/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537220
Principal investigator 1 Incyte Corporation $1,658.70 01/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537224
Principal investigator 1 Incyte Corporation $1,073.90 01/15/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537285
Principal investigator 1 Eli Lilly and Company $4,000.00 01/10/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187881016
Principal investigator 1 ABBVIE INC. $4,486.40 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202433839
Principal investigator 1 ABBVIE INC. $4,504.50 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202434800
Principal investigator 1 ABBVIE INC. $2,077.05 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202434804
Principal investigator 1 Incyte Corporation $190.80 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537185
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537188
Principal investigator 1 Incyte Corporation $206.70 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537193
Principal investigator 1 Incyte Corporation $132.50 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537197
Principal investigator 1 Incyte Corporation $100.70 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537201
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537205
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537209
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537216
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537240
Principal investigator 1 Incyte Corporation $185.50 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537289
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537293
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
GSI CLINICAL RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240537308